reference/34924659

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/34924659

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	1915
issn	0340-7004 1432-0851
issueIdentifier	6
pageRange	1903-1915
publicationName	Cancer immunology, immunotherapy : CII
startingPage	1903
bibliographicCitation	Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC investigators. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial. Cancer Immunol Immunother. 2023 Jun;72(6):1903–15. doi: 10.1007/s00262-023-03367-w. PMID: 36729213.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_994ee933f3095a0dacbd1a5a9e2db4d0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76eef0c8608f7c57062837533870dc52 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_53b42d056680d9956f1345f8097fcac9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_87a03b162b11b996a593a3af8264ee41 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_81785ccd8a992709f7816593c5c2b61f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bbc7d9f4bb12ada59f100fbd482133d9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_750e27ff50a198843644793502b2e583 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd6a67ece576952f05ac1871801a0db7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b0a92e1f223ff765627ce88ffec97243 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b9b20b1fb693a20a08e4e9641278cf85 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eec48a98f6315d7101285ab4c962219a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_32fb8f80a05abf486bc276648c711cd0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_247f0b6497f44a39e7f29c325749a5c6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dced2d91cc1d739b979454e2f3e4484c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_399238ed8620764eef435bc5fdf0a84a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b80a076e9cd375075346487452c6f400 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e58fda11e0441b97d6fa6ef1848a95e9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3acbfcf3c7be6c99795c60762b7d601a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_957226029467759b84354248e5fefc58 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_05e4d31abbae066a7ffb5a116be315f0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aec0219f0396e7180d964a1865851fd2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_70da9c0668b7eb4c1fa23422fe057137 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e72e81144a74fad7cfcc45e1cc5fca62 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cbf8893310fced62e2644d3a42352e44 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6bac9d6b9b45439a578066d13549aa81 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ae879a108844ff6308b21d6850d3d9fa
date	2023-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/36729213 https://doi.org/10.1007/s00262-023-03367-w
isPartOf	https://portal.issn.org/resource/ISSN/0340-7004 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2781 https://portal.issn.org/resource/ISSN/1432-0851
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial
discusses	http://id.nlm.nih.gov/mesh/M0585694
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9fbc5aa041b84b25d43b170290d2b89c http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7170 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b83d04d3e3b05ce10d1a5893dc850a9b http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9e1d2395fef36afb02c7a6e88eb06a74 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7a0153350cba31da4ce6bfa8f8c68f72

Total number of triples: 52.